The ASCO 2026 data are incrementally positive for olverembatinib's CML franchise and lisaftoclax's CLL/SLL program, but all drugs remain investigational in the US and no regulatory milestones were announced. The AGM approvals (share issuance/repurchase mandates, charter amendments) are routine governance. Monitor upcoming ASCO presentations (May 29–June 2) for investor reaction and any subsequent regulatory updates on POLARIS-2 or GLORA enrollment.
Price Chart
Executive Summary
Ascentage Pharma filed a 6-K furnishing its third amended and restated memorandum and articles of association (adopted May 20, 2026), poll results from its AGM (all resolutions passed, including approval of RSU/option grants to executives and a share repurchase mandate), and two clinical data announcements. The company released six abstracts (3 rapid oral, 3 poster) for ASCO 2026 covering its three lead drug candidates — olverembatinib, lisaftoclax, and alrizomadlin — across multiple hematologic and solid tumor indications. The data show encouraging efficacy signals (e.g., 91.3% CCyR rate for olverembatinib in second-line CP-CML; 30% ORR for alrizomadlin + lisaftoclax in pediatric sarcomas) and ongoing global Phase III registrational trials (POLARIS-2, GLORA). This is a routine pipeline update with no financial results or material corporate events.
Key Facts
- Six abstracts accepted at ASCO 2026 (May 29–June 2): 3 rapid oral, 3 poster presentations.
- Olverembatinib + blinatumomab Phase Ib: 4/5 MRD+ patients achieved CR, 2 achieved MRD negativity in R/R Ph+ BCP-ALL/CML-LBP.
- Olverembatinib second-line CP-CML (n=42 evaluable): CCyR 91.3%, MMR 60.9% at cycle 24; 81.3% CCyR in patients failing second-gen TKIs.
- Alrizomadlin ± lisaftoclax in pediatric sarcomas: monotherapy CR in 1 RMS patient; combination ORR 30%, DCR 80%, no DLTs.
- Olverembatinib in SDH-deficient GIST (n=26): 23.1% PR, median PFS 25.7 months; first evidence of p38-CD36 pathway inhibition.
- Global Phase III POLARIS-2 (olverembatinib in CML) and GLORA (lisaftoclax + BTKi in CLL/SLL) trials are actively enrolling.
- AGM held May 20, 2026: all 10 resolutions passed, including adoption of amended charter, share issuance mandate (20%), share repurchase mandate (10%), and RSU/option grants to CEO Dr. Yang Dajun and CMO Dr. Zhai Yifan.
- Third amended and restated memorandum and articles of association adopted by special resolution on May 20, 2026.
- No financial results, guidance, or material corporate transactions reported in this filing.
Financial Impact
No financial figures reported. Clinical data updates are non-financial and do not change revenue or earnings outlook.
Risk Factors
- All three lead candidates (olverembatinib, lisaftoclax, alrizomadlin) are not yet FDA-approved; clinical data are early-stage and non-registrational for most indications.
- POLARIS-2 and GLORA Phase III trials are still enrolling; no efficacy or safety readouts provided in this filing.
- AGM approved a 20% share issuance mandate and RSU/option grants to executives, creating potential future dilution.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-060305 |
| Document: ea029178201ex99-3.htm | 0001213900-26-060305 |
| Document: ea029178201ex99-1.htm | 0001213900-26-060305 |
| Document: ea029178201ex99-4.htm | 0001213900-26-060305 |
| Document: ea0291782-6k_ascentage.htm | 0001213900-26-060305 |
| Document: 0001213900-26-060305-index-headers.html | 0001213900-26-060305 |
| Document: 0001213900-26-060305-index.html | 0001213900-26-060305 |
| Document: 0001213900-26-060305.txt | 0001213900-26-060305 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 3d ago | 6-K | $14.92 | awaiting T+1 | — | $15.46 (+3.62%) |
Oct 21, 2026 4d ago | 6-K | $14.92 $15.44 | ▲ +3.49% | ▲ +4.01% | $15.46 (+3.62%) |
Oct 15, 2026 11d ago | 6-K | $14.69 $15.37 | ▲ +4.63% | ▲ +5.74% | $15.46 (+5.24%) |
Sep 17, 2026 5w ago | 6-K | $15.37 $15.06 | ▲ +2.02% | ▲ +1.90% | $15.46 (−0.59%) |
Aug 19, 2026 9w ago | Press Release | $17.32 $17.00 | ▲ +1.85% | ▲ +2.26% | $15.46 (+10.74%) |
Aug 5, 2026 11w ago | 6-K | $16.86 $17.09 | ▲ +1.39% | ▲ +1.55% | $15.46 (−8.28%) |
Aug 3, 2026 12w ago | 6-K | $16.81 $16.69 | ▼ −0.68% | ▼ −2.49% | $15.46 (−8.00%) |
Jul 26, 2026 13w ago | Press Release | $18.89 $18.29 | ▼ −3.20% | ▼ −3.44% | $15.46 (−18.16%) |
Jul 20, 2026 14w ago | 6-K | $18.37 $19.10 | ▲ +3.97% | ▲ +3.14% | $15.46 (−15.84%) |
Jul 13, 2026 14w ago | 6-K | $19.24 $20.18 | ▲ +4.89% | ▲ +4.49% | $15.46 (−19.65%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers